Loading
Countries track how bacteria become resistant to antibiotics and publish it. Doing the same for cancer drugs would show which escape routes are becoming common and where.
Routine post-progression sequencing already happens in health systems that offer routine tumour sequencing, but the results are not aggregated. A surveillance system, modelled on antimicrobial resistance reporting, would pool de-identified mechanism data by drug, line and region, publish periodic reports, and flag emerging mechanisms early. Laboratories would submit structured results as a condition of accreditation or reimbursement.
Shares Drug resistance (primary and acquired), Data silos, Acquired resistance to every therapy, Comprehensive genomic profiling.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos, Comprehensive genomic profiling.